Endodermal Cell Differentiation via Suspension Culture and Growth Factor Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating pluripotent stem cells into somatic cells through the three germ layers (endodermal, ectodermal, and mesodermal cells) lack efficiency and purity, necessitating enhanced differentiation induction and reduced undifferentiated cell content for therapeutic applications.
Innovation Solution
A method involving suspension culture of pluripotent stem cells with specific compounds like 2-mercaptoethanol, and the controlled addition or removal of factors such as TGFβ superfamily signaling activators, FGF2, and BMP4, to achieve a high proportion of SOX17-positive endodermal cells with reduced undifferentiated markers, resulting in a cell population suitable for cell therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional adhesion culture methods are used to differentiate pluripotent stem cells into endodermal cells, then the differentiation process can be maintained, but the differentiation efficiency and purity remain insufficient with high undifferentiated cell content
Solution Approach 1:
The patent applies parameter changes by switching from adhesion culture to suspension culture conditions, and by precisely controlling the concentration and timing of growth factors (TGFβ superfamily activators at 1-100 ng/mL, FGF2, BMP4) in the culture medium. These parameter modifications enable efficient differentiation into endodermal cells with 80% or higher SOX17 positivity while minimizing undifferentiated cell content
Solution Approach 2:
The patent implements preliminary action by pre-treating pluripotent stem cells with specific culture conditions and growth factor combinations before the main differentiation process. The cells are exposed to TGFβ superfamily signaling activators and other factors in a controlled sequence, preparing them for efficient endodermal differentiation and reducing undifferentiated cell persistence
2Manufacturing precision
If suspension culture with specific compounds is used to enhance differentiation efficiency, then endodermal cell purity increases, but the culture method complexity increases
Solution Approach 1:
The patent resolves the complexity issue by systematically defining specific culture parameters: suspension culture format, precise growth factor concentrations (TGFβ superfamily activators at 1-100 ng/mL, FGF2, BMP4), and defined time points for factor addition or removal. This structured parameter control achieves high endodermal purity (≥80% SOX17-positive cells) while making the protocol reproducible and manageable
3Quantity of substance
If growth factors are continuously supplied to maintain cell proliferation, then cell quantity increases, but differentiation induction efficiency decreases
Solution Approach 1:
The patent applies periodic action by implementing time-dependent growth factor supplementation strategies. Growth factors are added or removed at specific time points during the differentiation process rather than continuously, creating temporal patterns that first promote proliferation and then drive differentiation. This periodic control achieves both adequate cell quantity and high differentiation efficiency
Solution Approach 2:
The patent uses preliminary action by pre-exposing cells to specific growth factor combinations before initiating full differentiation. This preparatory phase allows cells to reach optimal state for differentiation while maintaining sufficient numbers, and subsequent controlled removal or modification of factors triggers efficient endodermal conversion
Data Source
AI summary
An object of the present invention is to provide an endodermal cell population for obtaining optimal somatic cells as cell therapy preparations. The endodermal cell population of the present invention has a reduced content proportion of undifferentiated cells in the cell population and contains endodermal cells differentiable into optimal somatic cells as cell therapy preparations. Further, a somatic cell derived from the endodermal cell population of the present invention has excellent therapeutic effects as a cell therapy preparation.